RESEARCH REFERENCE / BPC-157 + TB-500
BPC-157 TB-500 is a two-peptide research blend studied for vascular signaling and tissue repair.
Two structurally unrelated peptides, two characterized mechanisms, and one honest gap: no controlled study has ever measured them together. Every quantitative claim on this site is cited to its source.
What BPC-157 TB-500 is
BPC-157 TB-500 is not a single drug. It is a research-community pairing of two distinct synthetic peptides, distributed and discussed as a tissue-repair "stack" under the informal name Wolverine. The two are structurally unrelated and act through separate mechanisms.
BPC-157 (Body Protection Compound 157) is a 15-amino-acid pentadecapeptide, sequence GEPPPGKPADDAGLV, with a molecular weight near 1419.5 Da and CAS number 137525-51-0 [1]. It is a synthetic stable fragment of a protein found in human gastric juice. In the blend it supplies a local cytoprotective and pro-angiogenic signal.
TB-500 is a synthetic N-acetylated heptapeptide, Ac-LKKTETQ, with a molecular weight near 889 Da. It corresponds to residues 17-23 — the actin-binding motif — of the 43-residue intracellular protein Thymosin Beta-4 (UniProt P62328) [7]. In the blend it supplies a cytoskeletal cell-migration signal.
The blend has no single molecular weight, no CAS number, and no standardized ratio. The evidence for both constituents is overwhelmingly preclinical, and no controlled clinical trial of the combination exists for any indication [11]. This site documents what the published literature on each constituent actually measured — and marks, plainly, where it stops.
BPC-157 vs TB-500: Two Distinct Compounds
The two peptides are easy to conflate and easy to keep straight once the structures are read side by side. They share a tissue-repair narrative and almost nothing else.
What is the difference between BPC-157 and TB-500?
They are structurally unrelated. BPC-157 is a 15-amino-acid pentadecapeptide from a gastric-juice protein acting via VEGFR2/nitric-oxide and growth-hormone-receptor pathways [2][1]. TB-500 is a 7-amino-acid acetylated fragment of Thymosin Beta-4 acting by sequestering monomeric G-actin [3]. Different sequences, different sizes, different mechanisms.
A two-column reading: BPC-157 carries the BPC channel — cytoprotective and pro-angiogenic, GEPPPGKPADDAGLV, ~1419.5 Da, VEGFR2-Akt-eNOS [2]. TB-500 carries the TB channel — actin-binding and pro-migration, Ac-LKKTETQ, ~889 Da, 1:1 G-actin sequestration [3]. A reader should always know which constituent a given finding belongs to, because almost none of it overlaps.
Why the Research Community Pairs BPC-157 with TB-500
The case for pairing BPC-157 with TB-500 is mechanistic, not empirical. BPC-157 contributes a local angiogenic and cytoprotective signal; TB-500, through its parent protein Thymosin Beta-4, contributes a cytoskeletal cell-migration signal [4]. The two are described as covering different stages of tissue repair, which is why forum and supplier material proposes them together.
Why are BPC-157 and TB-500 combined (the Wolverine stack)?
The rationale is complementary mechanisms: BPC-157's local angiogenic and cytoprotective signal is paired with TB-500's cytoskeletal cell-migration signal, so the two are proposed to cover different stages of repair [2][3]. No head-to-head or combination study has defined a synergistic dose, ratio, or endpoint.
That last point is the load-bearing caveat. "Synergy" here is an extrapolation from two separately characterized — and largely non-overlapping — mechanisms, not a finding from any controlled combination study [11]. The why BPC-157 and TB-500 are combined section sets out the full evidence gap.
The Wolverine Peptide Blend: BPC-157 and TB-500 in Combination
Wolverine is the research-community and supplier name for the BPC-157 plus TB-500 pairing. It is a construct, not a compound: there is no CAS number for the blend, no standardized BPC-157:TB-500 ratio, and no approved product anywhere.
What is the Wolverine peptide blend?
A research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed and marketed as a tissue-repair "stack." It is not a single chemical entity, has no CAS number or standardized ratio, and is not an approved product anywhere [11].
Commercial vials are commonly labeled with a combined per-vial mass — for example, 10 mg BPC-157 plus 10 mg TB-500 — but that labeling reflects a packaging convention, not a clinically validated composition. Product identity, purity, and the actual ratio in unregulated material are not guaranteed [1]. For the angiogenesis mechanism that anchors this reference, see the BPC-157 and TB-500 angiogenesis research.
What the Blend Is Studied For
What is BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid pentadecapeptide (GEPPPGKPADDAGLV) derived from a human gastric-juice protein; TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to the actin-binding region of Thymosin Beta-4 [1][7]. The Wolverine blend pairs the two as a research-community tissue-repair stack.
What is the BPC-157 and TB-500 blend used for in research?
Preclinical, mostly rodent, research on the two constituents covers tendon, ligament, muscle and bone repair, wound and soft-tissue healing, and angiogenesis [5][6]. These are single-compound, animal-model findings; the blend itself has no controlled efficacy study [11].
The pages that follow keep the two constituents on separate channels throughout. The BPC-157 and TB-500 research findings page sets out the study record by tissue type; the BPC-157 and TB-500 dosage in animal models page covers research-handling parameters; and the Wolverine legal status and FDA 503A category page sets out where compounded access stands.